drugset / Trial / NCT03687034
A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
An Open-Label, Multi-Center Study to Assess the Safety and Pharmacokinetics of BRCX014 Combined with Standard-of-Care Treatment in Subjects with Glioblastoma
Timeline
- Start
- 2019-06-01
- Primary completion
- 2019-09-30
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Temozolomide | Small molecule | 75 mg/m2 | — |
| Background | Temozolomide | Small molecule | 150 mg/m2 | — |
| Background | Temozolomide | Small molecule | 200 mg/m2 | — |